JPRN-jRCTs031220736招募中2 期
A clinical trial of Tazemetostat for pediatric and AYA patients with malignant tumors which have no standard of care or and which is refractory to standard of care: Patients-Proposed Healthcare Service - NCCH2214 trial (TURTLE trial)
OGAWA Chitose0 个研究点目标入组 10 人开始时间: 2023年3月27日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 6month old 至 <= 29age old（—）
- 性别
- All
入选标准
- •1) Diagnosis of malignant solid tumor by histological or cytological diagnosis; If the histopathological examination was performed prior to enrollment, the timing of the examination is not required. However, if the histopathological examination was performed at another hospital, the pathological specimen must be ordered and the pathological diagnosis must be made again at each study site.
- •2) One of the following (1) to (3) applies
- •(1) Tazemetostat is recommended by the expert panel of the gene panel test that has been covered by insurance or conducted as an evaluationtreatment in Japan.
- •(2) Reduced expression or loss of INI1 or SMARCA 4 by immunostaining.
- •(3) Diagnosis name is rhabdoid tumor (AT/RT, MRT, RTK), epithelioid sarcoma, synovial sarcoma, chordoma
- •3) No standard treatment or refractory to standard treatment
- •4) The patient is not eligible of a corporate clinical trial, investigator-initiated clinical trial, or adva
- •nced medical treatment being conducted at a medical institution in Japan.
- •5) The patient does not have symptomatic brainmetastases, cancerous meningitis, or spinal metastases requiring irradiation or surgical procedures.
- •6) No pericardial, pleural, or ascites effusions requiring treatment.
- •7) Patients must be between 6 months and 29 years of age at the time of enrollment and have a body surface area of at least 0.17 m2 for patients with CNS tumors and 0.39 m2 for patients without CNS tumors.
- •8) Karnofsky score (for age 16 years and older) or Lansky score (for age 15 years and younger) of 50 or higher
- •9) Neoplastic lesions can be confirmed by contrast-enhanced CT or MRI (head, chest, abdomen, pelvis: slice thickness 5 mm or less) within 28 days prior to the date of registration (the same day of the week is acceptable as follows) (regardless of whether measurable lesions are present).
- •10) Patient has been treated with chemotherapy (treatment in this study is the second or subsequent treatment)
- •11) Patients with brain tumors have not receivedany new or increased dose of corticosteroids administered intravenously or orally between 7 days prior to and on the day of a contrast-enhanced MRI brain scan performed within 28 days prior to enrollment. If a new or increased dose of corticosteroid medication is administered between the cerebral contrast-enhanced MRI and the start of protocol treatment, a repeat baseline cerebral contrast-enhanced MRI must be performed before the start of protocol treatment.
- •12) Have not received any anticancer drug (chemotherapy, molecular targeted therapy,immunotherapy, etc.) or other study drug within 28 days prior to the date of enrollment
- •13) Have not undergone surgery involving general anesthesia within 28 days prior to enrollment
- •14) Have not received radiotherapy (including Gamma Knife and CyberKnife) within 14 days prior to enrollment
- •15) Clinical examinations performed within 14 days prior to the date of enrollment meet the following criteria: (1) to (7). However, the patient must not have received granulocyte colony stimulating factor (G-CSF product) administration or blood transfusion within 14 days prior to the date of blood collection
- •(1) Neutrophil count =>1,000 /mm3
- •(2) Platelet count =>7.5 x 104/mm3
- •(3) Hemoglobin =>8.0 g/dL
- •(4) AST <= 3 times the upper limit of clinical laboratory standards
- •(5) ALT <= 3 times the upper limit of clinical laboratory standards
- •(6) Total bilirubin <= 1.5 times the upper limit of clinical laboratory standards
- •(7) Serum creatinine <= 1.5 times the upper
排除标准
- •1) Patients with active overlapping cancers (the following (1) to (3) are not excluded:
- •(1) the following cancers that have been completely resected: basal cell carcinoma, stage I spinous cell carcinoma, intraepithelial carcinoma, intramucosal carcinoma, superficial bladder cancer
- •(2) gastrointestinal cancer curatively resected by ESD or EMR
- •(3) other cancer that has not recurred for at least 5 years
- •2) Infectious disease requiring systemic treatment
- •3) Complicated active gastrointestinal ulcer
- •4) Complicated or pre-existing interstitial lung dis ease or pulmonary fibrosis diagnosed by imaging or clinical findings
- •5) Has a history of hypersensitivity reaction to tazemetostat
- •6) Previous administration of EZH2 inhibitors such as tazemetostat or valemetostat, with a history of ineffectiveness or discontinuation due to adverse events
- •7) Previous allogeneic hematopoietic stem cell transplantation.
- •8) Autologous hematopoietic stem cell transplantation within 12 weeks (84 days) prior to enrollment.
- •9) Has positive HIV antibody, HBs antigen, or HCV antibody (however, patients with positive HCV a ntibody but no detectable HCV RNA are not exclu ded).
- •10) HBs antigen negative, HBs antibody or HBc a ntibody positive, and HBV-DNA quantification pos itive (patients are not excluded if the sensitivity is l ess than the detection sensitivity).
- •11) Pregnant or lactating women who need to co ntinue breastfeeding or who may be pregnant afte r the start of study drug administration
- •12) Patients with psychosis or psychiatric sympto ms that interfere with daily life and make it difficul t for them to participate in the study.
- •13) History of any of the following (within 6 months prior to enrollment) or complications
- •(1) Diabetes mellitus judged to be poorly controlled
- •(2) Chronic congestive heart failure (Class III or hi gher of the New York Heart Association (NYHA) ca rdiac function classification)
- •(3) History of unstable angina, angioplasty, stent g raft and implantation, or myocardial infarction
- •(4) Symptomatic or treatable arrhythmia or asympt omatic sustained ventricular tachycardia (except controllable a symptomatic atrial fibrillation)
- •(14) QT corrected for HR using Fridericia's metho d (QTcF) interval >470 ms on a 12 lead ECG perfo rmed within 14 days prior to enrollment.
- •(15) Other conditions for which the principal investigator or research assistant investigator consider s the subject to be ineligible.
研究者
相似试验
招募中
2 期
CCH2107/MK012 trialEpithelioid SarcomaLoss of INI1 protein, Epithelioid SarcomaD012509JPRN-jRCT2031220523Yonemori Kan15
已完成
2 期
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)Advanced Malignant Solid NeoplasmAnn Arbor Stage III Hodgkin LymphomaAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaEwing Sarcoma/Peripheral Primitive Neuroectodermal TumorLow Grade GliomaRecurrent EpendymomaRecurrent Ewing SarcomaRecurrent GliomaRecurrent HepatoblastomaRecurrent Hodgkin LymphomaRecurrent Langerhans Cell HistiocytosisRecurrent Malignant Germ Cell TumorRecurrent Malignant GliomaRecurrent Malignant Solid NeoplasmRecurrent MedulloblastomaRecurrent NeuroblastomaRecurrent Non-Hodgkin LymphomaRecurrent OsteosarcomaRecurrent Peripheral Primitive Neuroectodermal TumorRecurrent Primary Central Nervous System NeoplasmRecurrent Rhabdoid TumorRecurrent RhabdomyosarcomaRecurrent Soft Tissue SarcomaRefractory Hodgkin LymphomaRefractory Langerhans Cell HistiocytosisRefractory Malignant Germ Cell TumorRefractory Malignant GliomaRefractory Malignant Solid NeoplasmRefractory MedulloblastomaRefractory NeuroblastomaRefractory Non-Hodgkin LymphomaRefractory OsteosarcomaRefractory Peripheral Primitive Neuroectodermal TumorRefractory Rhabdoid TumorRefractory Soft Tissue SarcomaRhabdoid TumorStage III Soft Tissue Sarcoma AJCC v7Stage IV Soft Tissue Sarcoma AJCC v7Wilms TumorNCT03213665National Cancer Institute (NCI)20
撤回
1 期
Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver DysfunctionAnn Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaMetastatic Malignant Solid NeoplasmStage III Hepatocellular Carcinoma AJCC v7Stage IIIA Hepatocellular Carcinoma AJCC v7Stage IIIB Hepatocellular Carcinoma AJCC v7Stage IIIC Hepatocellular Carcinoma AJCC v7Stage IV Hepatocellular Carcinoma AJCC v7Stage IVA Hepatocellular Carcinoma AJCC v7Stage IVB Hepatocellular Carcinoma AJCC v7Unresectable Solid NeoplasmNCT03217253National Cancer Institute (NCI)
进行中（未招募）
2 期
Tazemetostat in Malignant Peripheral Nerve Sheath TumorsPeripheral Nerve Sheath TumorNCT04917042University of Florida10
进行中（未招募）
1 期
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Urothelial CarcinomaStage III Bladder Cancer AJCC v8Stage IV Bladder Cancer AJCC v8NCT03854474National Cancer Institute (NCI)30